Recently, tyrosine kinase activation of EGFR was shown to enhance the activity of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), an essential glycolytic activator for the synthesis and degradation of fructose-2,6-bisphosphate (F26BP) that contributes to the survival of NSCLC cells [18]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.